A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis-Reference-Cited by-同舟云学术

A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis

Published:2023-05-28 Issue:9 Volume:270 Page:4403-4414
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Louapre C.^ORCID,Rosenzwajg M.^ORCID,Golse M.,Roux A.,Pitoiset F.,Adda L.,Tchitchek N.,Papeix C.,Maillart E.,Ungureanu A.,Charbonnier-Beaupel F.,Galanaud D.,Corvol J. C.,Vicaut E.,Lubetzki C.,Klatzmann D.^ORCID

Funder

Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques

ANR

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s00415-023-11690-6.pdf

Reference41 articles.

1. Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neuron 97:742–768. https://doi.org/10.1016/j.neuron.2018.01.021

2. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199:971–979. https://doi.org/10.1084/jem.20031579

3. Dominguez-Villar M, Baecher-Allan CM, Hafler DA (2011) Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med 17:673–675. https://doi.org/10.1038/nm.2389

4. Goverman JM (2021) Regulatory T cells in multiple sclerosis. N Engl J Med 384:578–580. https://doi.org/10.1056/NEJMcibr2033544

5. Bar-Or A, Li R (2021) Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurol 20:470–483. https://doi.org/10.1016/S1474-4422(21)00063-6

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial;2024-09-04

2. Peroxynitrite reduces Treg cell expansion and function by mediating IL-2R nitration and aggravates multiple sclerosis pathogenesis;Redox Biology;2024-09

3. Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial;Brain, Behavior, and Immunity;2024-09

4. Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial;2024-07-19

5. Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers;Brain, Behavior, and Immunity;2024-05